Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair.AVTE's AV-101 failed due to dose limitations and ...
Source LinkGossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair.AVTE's AV-101 failed due to dose limitations and ...
Source Link
Comments